ESC 2023
(10 contents)
ESC 2023
Introduction and Part 1: Addressing New Guidelines
EN
Presented at ESC 2023 in Amsterdam, NL, this symposium provides an excellent opportunity to learn about the latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
ESC 2023
Part 2: Patient Vignette
EN
Presented at ESC 2023 in Amsterdam, NL, this session presents a newly diagnosed HFpEF patient and demonstrates barriers to GDMT.
ESC 2023
Part 3: Early / Rapid Initiation of GDMT
EN
Presented at ESC 2023 in Amsterdam, NL, the panel discuss latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
ESC 2023
Part 4: Anticipating Barriers in HFpEF
EN
Presented at ESC 2023 in Amsterdam, NL, the panel provide valuable insights into the challenges and barriers faced while adopting new guideline-directed medical therapy for heart failure patients.
ESC 2023
Part 5: The Heart Failure Team
EN
Presented at ESC 2023 in Amsterdam, NL, this session emphasises the significance of cross-functional teams in managing heart failure therapy.
ESC 2023
Part 6: Audience Q&A and Panel Discussion
EN
Presented at ESC 2023 in Amsterdam, NL, this session closes with audience Q&A and panel discussion.
ESC 2023
Part 1: ATTR – A Multi-system Disease Posing Unique Challenges
EN
Presented at ESC 2023 in Amsterdam, NL, this symposium provides you with the practical knowledge and tools to implement ATTR-cm effectively in your clinical practice.
ESC 2023
Part 2: Assessing Cardiac Manifestations of ATTR
EN
Presented at ESC 2023 in Amsterdam, NL, Dr Grogan uses a patient journey to discuss the cardiac implications of ATTR and the diagnosis and monitoring of symptomatic cases with ATTR-cm.
ESC 2023
Part 3: Long-term Management
EN
Presented at ESC 2023 in Amsterdam, NL, Dr Obici focuses on tracking disease progression by evaluating multiple symptoms and their assessment frequency, involving various healthcare professionals.
ESC 2023
Part 4: What’s in our Future Toolbox?
EN
Presented at ESC 2023 in Amsterdam, NL, Prof Kristen delves into the realm of innovative pharmacological management.
CME Courses
(4 contents)
CME Courses
The Advancing Management of Transthyretin Amyloidosis: A Practical Guide
CME Courses
Examining a Complex Heart Failure Case
CME Courses
Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management
CME Courses
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
Guidelines
(9 contents)
Guidelines
HF Guideline Review Part 1: Distilling the New ESC Guideline Update
EN
Prof Lam and Prof Rosano discuss why there was a need for an update of the 2021 guidelines, and consider the changing landscape following several randomised controlled trials.
Guidelines
HF Guideline Review Part 2: Assessing the Impact on Practice
EN
Prof Lam and Prof Rosano consider the recommendations for SGLT2 inhibitor use, to reduce cardiovascular death and heart failure hospitalisation, and the expected impact on clinical practice.
Guidelines
HF Guideline Review Part 3: The Future of Heart Failure Management
EN
Prof Lam and Prof Rosano discuss the power of early detection in improving outcomes and stress the need for accessible and efficient diagnostic testing for the prevention of heart failure among high-risk patients.
Guidelines
Re-Evaluating GDMT in Heart Failure: Part 1 - Accommodating New Evidence in HF Guidelines
EN
Dr Savarese and Dr Bozkurt summarise the 2022 American guidelines new recommendations for pharmacological agents in HF and the evidence that was unavailable in the 2021 European guidelines.
Guidelines
Re-Evaluating GDMT in Heart Failure: Part 2 - Current Trends in HF GDMT
EN
Dr Savarese and Dr Vardeny discuss the recent guideline recommendations for four pillar GDMT and how well these are being utilised in clinical practice for patients with HF.
Guidelines
What is GDMT?
EN
Prof Coats and Dr Kosiborod summarise foundational guideline-directed medical therapy (GDMT) across the spectrum of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Guidelines
Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano address key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF.
Guidelines
Guideline Directed Medical Therapy in HF
EN
In this short peer-to-peer discussion, Dr Biykem Bozkurt, and Prof Giuseppe Rosano, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Guidelines
SGLT-2 Inhibitors Across the Range Of EF
EN
In this short peer-to-peer discussion, Prof Giuseppe Rosano and Dr Mikhail Kosiborod, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Heart Failure in Focus Podcast
(7 contents)
Podcasts
Episode 7: The Evolving Role of Primary Care in HF
EN
Dr Muthiah Vaduganathan is joined by Prof Xavier Cos, a general practitioner and Chairman of Primary Care Diabetes Europe, to discuss the current and future role of primary care in heart failure (HF).
Podcasts
Episode 6: Cardiorenal Care in Practice
EN
Dr Muthiah Vaduganathan speaks with Dr Kieran McCafferty, Consultant Nephrologist at Barts NHS Health Trust London, about the growing need for effective management strategies in cardiorenal disease.
Podcasts
Episode 5: Functional & QoL Outcomes in a Sea of Clinical Event Data
EN
Dr Vaduganathan is joined by Dr Mikhail Kosiborod, leading expert on Quality of Life (QoL) instruments world-wide, to discuss functional and QoL outcomes of foundational therapies in Heart Failure (HF) and the clinical application of this data.
Podcasts
Episode 4: Mitigating Clinical Inertia in Heart Failure
EN
Dr Vaduganathan is joined by Dr Tariq Ahmad to discuss the reality of sub-optimal treatment and possible ways forward using behavioural “nudges” embedded within electronic health records.
Podcasts
Episode 3: 4 Onboard: Implementing GDMT
EN
Dr Vaduganathan is joined by Dr Biykem Bozkurt, for the third episode, to discuss some of the most challenging questions around implementing guideline directed medical therapy (GDMT).
Podcasts
Episode 2: Your Questions Answered
EN
Dr Vaduganathan is joined by Prof Carolyn Lam to continue the theme of SGLT-2 inhibitors in heart failure. Listen to them answer your questions about SGLT-2 inhibitors and the practical management of heart failure patients.
Podcasts
Episode 1: Emerging Data from the ESC
EN
Dr Muthiah Vaduganathan is joined by Prof Scott Solomon for the first episode in this new series, Heart Failure in Focus, to discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona.
Implementation
(7 contents)
Implementation
Practically Implementing PROMs
EN
In this final part of this series, Dr Kosiborod and Dr Zieroth discuss practical implication of these patient reported outcome measures (PROMs).
Implementation
Initiating SGLT-2 Inhibitors
EN
Prof Rosano and Dr Bozkurt examine recent guidelines and consider best practice for initiating SGLT-2 inhibitors across the continuum of HF and in patients already on HF medication versus those who are treatment-naïve.
Implementation
Early Initiation and Better Clinical Outcomes
EN
Prof Coats and Dr Kosiborod discuss the relationship between early initiation of foundational GDMT and better clinical outcomes by exploring recent clinical trial data from STRONG-HF.
Implementation
Achieving Early Uptake of GDMT
EN
In this final part, Prof Coats and Dr Kosiborod cover practical approaches for ensuring early optimal GDMT in heart failure, such as, the use of electronic health records and protocols for specific patient subgroups.
Implementation
Implementation Strategies for GDMT in Respect of the New Guidelines
EN
In this short interview, Dr Kosiborod and Dr Van Spall summarise some of the key changes in guidance following the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Implementation
When and How to Initiate SGLT-2 Inhibitors in HFrEF
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano provide a comprehensive update on when and how to initiate SGLT-2 inhibitors.
Implementation
Evolving the Management Approach - AEs and MDTs
EN
Prof Rosano and Dr Bozkurt discuss the practicalities of continual management of HF patients on an SGLT-2 inhibitor and how the broader multidisciplinary team should be aware of the benefits of early SGLT-2 initiation in HF.
Optimising Therapy
(7 contents)
Optimising Therapy
Optimising Treatment of HF
EN
In part one of this programme 'Optimising Treatment of HF', Prof Cowie introduces the topic and reviews the learning objectives.
Optimising Therapy
New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
EN
In part three of 'Optimising Treatment of HF', Dr Butler presents a case, and considers available treatment strategies and the optimal approach for HFrEF medications.
Optimising Therapy
Existing HF-REF: Augmenting the SOC
EN
In part four of 'Optimising Treatment of HF', Dr Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.
Optimising Therapy
How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
EN
In the final part of this programme 'Optimising Treatment of HF', Prof Cowie moderates a discussion with the faculty.
Optimising Therapy
Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice
EN
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano discuss how to make evidence-based choices in the selection of SGLT-2 inhibitors.
Optimising Therapy
Using Guideline Directed Medical Therapy to Improve Outcomes
EN
In this short peer-to-peer discussion, Prof Giuseppe Rosano and Dr Mikhail Kosiborod, discuss the main updates from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Optimising Therapy
QoL and Functional Measures of Treatment Success
EN
Dr Kosiborod and Dr Zieroth discuss QoL and functional status as tangible measurements of treatment success.
Trial Data
(5 contents)
Trial Data
Clinical Evidence
EN
Dr Kosiborod and Dr Zieroth look at the relationship between initiating GDMT and QoL / functional status improvement. They discuss some of the specific clinical trial data showing how initiating SGLT-2 inhibitors improves QoL and functional outcomes.
Trial Data
The DELIVER Trial in Brief
EN
Prof Lam discusses DELIVER with one of the trial’s lead investigators, Prof McMurray. As well as the key results from DELIVER, they consider how to apply them to HFpEF patients in the real-world.
Trial Data
DELIVER and DAPA-HF Pooled Analysis in Brief
EN
Prof Lam and Prof McMurray put into context the pooled analysis of DELIVER and DAPA-HF and consider whether these results can be extrapolated to the entire HF population, addressing the suitability of patients according to their individual EF.
Trial Data
The PRESERVED-HF Study: Effects of Dapagliflozin
EN
In this short presentation on behalf of the investigators, Dr Kosiborod summarises the PRESERVED-HF study, looking at effects of Dapagliflozin on symptoms and functional status in patients with HF and preserved EF.
Trial Data
A Review of Recent SGLT2 Inhibitor Data
EN
In part two of 'Optimising Treatment of HF', Prof Rosano reviews recent SGLT2 trial data, including DAPA-HF and EMPEROR-Reduced.
Complex Patients
(13 contents)
Complex Patients
Examining a Complex Heart Failure Case: Part 1 - Approaching the Patient
EN
The multidisciplinary panel discuss their initial approach to a patient from the perspective of their different backgrounds and how they can most effectively manage this patient as a team.
Complex Patients
Examining a Complex Heart Failure Case: Part 2 - Diagnosing the Patient
EN
The panel discuss labelling the patient with a diagnosis, prioritising problems for management and ask who should start foundational therapy of SGLT-2 inhibitors.
Complex Patients
Examining a Complex Heart Failure Case: Part 3 - Managing the Patient
EN
The panel review poll results from the audience on approach to management, discuss their approach to initiating GDMT and explore overcoming a dip in renal function following SGLT-2 inhibition.
Complex Patients
Examining a Complex Heart Failure Case: Part 4 - Follow-up & Referral
EN
The panel now discuss the ongoing patient centred care required for this patient, continued investigation and holistic co-management.
Complex Patients
Examining a Complex Heart Failure Case: Part 5 - Responding to a Changing Patient
EN
The panel discuss how they would continue to manage the patient with foundational therapy as their symptoms, disease severity and comorbidities change over time.
Complex Patients
Examining a Complex Heart Failure Case: Part 6 - Re-cap and Summary
EN
Prof Coats closes this programme by summarising key learning points from this complex case of HFpEF.
Complex Patients
Ejection Fraction - How Important Is It Today?
EN
During the first part of this roundtable, chaired by Prof Cowie, our multidisciplinary panel discuss the importance of EF, and analyse survey data.
Complex Patients
HFrEF and HFpEF Case Review
EN
During the second part of this roundtable, our multidisciplinary panel discuss two patient cases and their treatment strategies based on recent guidelines and data updates.
Complex Patients
The Expanding Role of Primary Care in Ongoing HF Management
EN
During the final part of this roundtable, the panel discuss the role of primary care in ongoing heart failure management.
Complex Patients
Screening for CKD
EN
Prof Khunti addresses the burden of CKD globally, including the prevalence of CKD in patients with type 2 diabetes. The faculty discuss existing tools for screening for CKD, and the recommendations of international guidelines.
Complex Patients
Treatment Options in CKD
EN
Dr Zieroth enquires of the latest treatment options for CKD, with Prof Heerspink advising on evidence supporting the use of treatments, whilst Prof Khunti provides insight to the role of initiating SGLT2 therapy, and underlines the urgency to treat.
Complex Patients
Effects of Dapagliflozin in Patients With Chronic Kidney Disease
EN
In this presentation of the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof McMurray provides a comprehensive overview of the study's background, methods and results.
Complex Patients
Cardio-renal Pathophysiology
EN
Prof Khunti outlines what clinicians need to know about the relationship between chronic kidney disease and cardiovascular disease. Prof Heerspink addresses why clinicians should be encouraged to intervene early for patients living with CKD.
HFA 2023
(3 contents)
HFA 2023
The Urgency to Implement GDMT
EN
In this first session of this symposium entitled 'Overcoming the Challenges in Optimising GDMT in HF', the panel delve into the urgency of implementing GDMT for patients with heart failure.
HFA 2023
Barriers to Achieving Optimal Medical Therapy
EN
In the second session, the panel engage in a thought-provoking discussion about the barriers that impede the achievement of optimal medical therapy.
HFA 2023
Practical Strategies to Implement New Algorithms in GDMT
EN
In the final session, the panel aims to equip attendees with practical strategies to navigate the complexities of implementing new algorithms in GDMT and improving patient care.
ESC 2022
(4 contents)
ESC 2022
SGLT2 Inhibitors: Light at the End of the Tunnel
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
SGLT2 Inhibitors Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
Practical Considerations for Treating HF With Mildly Reduced and Preserved EP
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
ESC 2022
Implementing Best Practices Across the Spectrum of Heart Failure
EN
Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice.
HFO 2022
(3 contents)
HFO 2022
The ACC Heart Failure Guidelines 2022: What Did We Learn?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.
HFO 2022
The Future of Guidelines: Towards Personalised Care?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.
HFO 2022
HFpEF: The Final Chapter in the Heart Failure Story?
EN
This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.